Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Margherita RiminiLorenzo FornaroSara LonardiMonica NigerDaniele LavacchiTiziana PressianiJessica LucchettiGuido GiordanoAndrea PrettaEmiliano TamburiniChiara PirroneIlario Giovanni RapposelliAnna DianaErika MartinelliIngrid GarajováFrancesca SimionatoMarta SchirripaVincenzo FormicaCaterina VivaldiEnrico CalimanMario Domenico RizzatoValentina ZanusoFederico NichettiLorenzo AngottiMatteo LandriscinaMario ScartozziMatteo RamundoAlessandro PastorinoBruno DanieleNoemi CornaraMara PersanoEleonora GusmaroliRiccardo CerantolaFrancesca SalaniFrancesca RattiLuca AldrighettiStefano CascinuLorenza RimassaLorenzo AntonuzzoStefano CascinuPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
The results reported in this first real-world analysis mostly confirmed the results achieved in the TOPAZ-1 trial in terms of PFS, ORR and safety.